Cardiovascularis biztonságossági vizsgálatok SGLT-2-gátló antidiabetikumokkal 2-es típusú diabetesben

Translated title of the contribution: Clinical trials for evaluating cardiovascular safety of sglt-2-inhibitor drugs in patients with type 2 diabetes

Research output: Contribution to journalArticle

Abstract

SGLT-2-inihibitors are considered as a new class among oral antidiabetic drugs. The first derivatives of this class became available in the last couple of years in Hungary. According to the requirements from regulatory bodies, randomized, controlled clinical trials have been initiated in order to evaluate the cardiovascular safety of nearly all new antidiabetic drugs in patients with type 2 diabetes. Among SGLT-2-inhibitors, only one trial with empagliflozine has been completed so far. Based on the endpoints of the EMPA-REG OUTCOME trial a significant decrease in different cardiovascular events and total mortality was observed in type 2 diabetic patients with elevated cardiovascular risk. The exact pathomechanism of this beneficial effect has not been clearly understood. Currently, the position statements and scientific guidelines clearly describe the place of SGLT-2-inhibitor drugs in the treatment algorithm; the beneficial effect of empagliflozine on cardiovascular events should seriously be considered when making therapeutic decision. Together with the results of ongoing studies with SGLT-2-inhibitors (dapagliflozine: DECLARE, canagliflozine: CANVAS), these data will provide a more robust evidence about the cardiovascular safety of this new class of oral antidiabetic drugs.

Original languageHungarian
Pages (from-to)93-99
Number of pages7
JournalLege Artis Medicinae
Volume26
Issue number3
Publication statusPublished - 2016

Fingerprint

Hypoglycemic Agents
Type 2 Diabetes Mellitus
Clinical Trials
Safety
Pharmaceutical Preparations
Hungary
Decision Making
Randomized Controlled Trials
Guidelines
Mortality
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{927d55a87f06441ba1ed5a64ae13fa36,
title = "Cardiovascularis biztons{\'a}goss{\'a}gi vizsg{\'a}latok SGLT-2-g{\'a}tl{\'o} antidiabetikumokkal 2-es t{\'i}pus{\'u} diabetesben",
abstract = "SGLT-2-inihibitors are considered as a new class among oral antidiabetic drugs. The first derivatives of this class became available in the last couple of years in Hungary. According to the requirements from regulatory bodies, randomized, controlled clinical trials have been initiated in order to evaluate the cardiovascular safety of nearly all new antidiabetic drugs in patients with type 2 diabetes. Among SGLT-2-inhibitors, only one trial with empagliflozine has been completed so far. Based on the endpoints of the EMPA-REG OUTCOME trial a significant decrease in different cardiovascular events and total mortality was observed in type 2 diabetic patients with elevated cardiovascular risk. The exact pathomechanism of this beneficial effect has not been clearly understood. Currently, the position statements and scientific guidelines clearly describe the place of SGLT-2-inhibitor drugs in the treatment algorithm; the beneficial effect of empagliflozine on cardiovascular events should seriously be considered when making therapeutic decision. Together with the results of ongoing studies with SGLT-2-inhibitors (dapagliflozine: DECLARE, canagliflozine: CANVAS), these data will provide a more robust evidence about the cardiovascular safety of this new class of oral antidiabetic drugs.",
keywords = "Antidiabetic treatment, Cardiovascular risk, Dapagliflozine, Empagliflozine, Heart failure, SGLT-2-inhibitors, Type 2 diabetes",
author = "G. Jermendy",
year = "2016",
language = "Hungarian",
volume = "26",
pages = "93--99",
journal = "Lege Artis Medicinae",
issn = "0866-4811",
publisher = "Literatura Medica Publishing House",
number = "3",

}

TY - JOUR

T1 - Cardiovascularis biztonságossági vizsgálatok SGLT-2-gátló antidiabetikumokkal 2-es típusú diabetesben

AU - Jermendy, G.

PY - 2016

Y1 - 2016

N2 - SGLT-2-inihibitors are considered as a new class among oral antidiabetic drugs. The first derivatives of this class became available in the last couple of years in Hungary. According to the requirements from regulatory bodies, randomized, controlled clinical trials have been initiated in order to evaluate the cardiovascular safety of nearly all new antidiabetic drugs in patients with type 2 diabetes. Among SGLT-2-inhibitors, only one trial with empagliflozine has been completed so far. Based on the endpoints of the EMPA-REG OUTCOME trial a significant decrease in different cardiovascular events and total mortality was observed in type 2 diabetic patients with elevated cardiovascular risk. The exact pathomechanism of this beneficial effect has not been clearly understood. Currently, the position statements and scientific guidelines clearly describe the place of SGLT-2-inhibitor drugs in the treatment algorithm; the beneficial effect of empagliflozine on cardiovascular events should seriously be considered when making therapeutic decision. Together with the results of ongoing studies with SGLT-2-inhibitors (dapagliflozine: DECLARE, canagliflozine: CANVAS), these data will provide a more robust evidence about the cardiovascular safety of this new class of oral antidiabetic drugs.

AB - SGLT-2-inihibitors are considered as a new class among oral antidiabetic drugs. The first derivatives of this class became available in the last couple of years in Hungary. According to the requirements from regulatory bodies, randomized, controlled clinical trials have been initiated in order to evaluate the cardiovascular safety of nearly all new antidiabetic drugs in patients with type 2 diabetes. Among SGLT-2-inhibitors, only one trial with empagliflozine has been completed so far. Based on the endpoints of the EMPA-REG OUTCOME trial a significant decrease in different cardiovascular events and total mortality was observed in type 2 diabetic patients with elevated cardiovascular risk. The exact pathomechanism of this beneficial effect has not been clearly understood. Currently, the position statements and scientific guidelines clearly describe the place of SGLT-2-inhibitor drugs in the treatment algorithm; the beneficial effect of empagliflozine on cardiovascular events should seriously be considered when making therapeutic decision. Together with the results of ongoing studies with SGLT-2-inhibitors (dapagliflozine: DECLARE, canagliflozine: CANVAS), these data will provide a more robust evidence about the cardiovascular safety of this new class of oral antidiabetic drugs.

KW - Antidiabetic treatment

KW - Cardiovascular risk

KW - Dapagliflozine

KW - Empagliflozine

KW - Heart failure

KW - SGLT-2-inhibitors

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=84990834269&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84990834269&partnerID=8YFLogxK

M3 - Article

VL - 26

SP - 93

EP - 99

JO - Lege Artis Medicinae

JF - Lege Artis Medicinae

SN - 0866-4811

IS - 3

ER -